These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34028105)

  • 1. Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
    Narita T; Hatakeyama S; Numakura K; Kobayashi M; Muto Y; Saito M; Narita S; Tanaka T; Noro D; Tokui N; Yoneyama T; Hashimoto Y; Habuchi T; Ohyama C
    Int J Urol; 2021 Sep; 28(9):899-905. PubMed ID: 34028105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab.
    Kato M; Kobayashi T; Matsui Y; Ito K; Hikami K; Yamada T; Ogawa K; Nakamura K; Sassa N; Yokomizo A; Abe T; Tsuchihashi K; Tatarano S; Inokuchi J; Tomida R; Fujiwara M; Takahashi A; Matsumoto K; Shimizu K; Araki H; Kurahashi R; Ozaki Y; Tashiro Y; Uegaki M; Kojima T; Uchida J; Ogawa O; Nishiyama H; Kitamura H;
    Int J Urol; 2021 Dec; 28(12):1261-1267. PubMed ID: 34545627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
    Shindo T; Hashimoto K; Takahashi A; Miyamoto S; Kunishima Y; Sato S; Fukuta F; Hiyama Y; Takayanagi A; Kato R; Wanifuchi A; Ueki Y; Okada M; Adachi H; Kobayashi KO; Tanaka T; Masumori N;
    Anticancer Res; 2024 Mar; 44(3):1271-1279. PubMed ID: 38423657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study.
    Furubayashi N; Morokuma F; Tomoda T; Hori Y; Negishi T; Miura A; Komori H; Kuroiwa K; Nakamura M
    Anticancer Res; 2022 Mar; 42(3):1571-1577. PubMed ID: 35220254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
    Massari F; Santoni M; Takeshita H; Okada Y; Tapia JC; Basso U; Maruzzo M; Scagliarini S; Büttner T; Fornarini G; Myint ZW; Galli L; Souza VC; Pichler R; De Giorgi U; Gandur N; Lam ET; Gilbert D; Popovic L; Grande E; Mammone G; Berardi R; Crabb SJ; Kemp R; Molina-Cerrillo J; Freitas M; Luz M; Iacovelli R; Calabrò F; Tural D; Atzori F; Küronya Z; Chiari R; Campos S; Caffo O; Fay AP; Kucharz J; Zucali PA; Rinck JA; Zeppellini A; Bastos DA; Aurilio G; Mota A; Trindade K; Ortega C; Sade JP; Rizzo M; Fiala O; Vau N; Giannatempo P; Barillas A; Monteiro FSM; Dauster B; Mennitto A; Nogueira L; de Carvalho Fernandes R; Seront E; Aceituno LG; Grillone F; Cutuli HJ; Fernandez M; Bassanelli M; Kopp RM; Roviello G; Abahssain H; Procopio G; Milella M; Kopecky J; Martignetti A; Messina C; Caitano M; Inman E; Kanesvaran R; Herchhorn D; Santini D; Bamias A; Bisonni R; Mosca A; Morelli F; Maluf F; Soares A; Nunes F; Pinto A; Zgura A; Incorvaia L; Ansari J; Zabalza IO; Landmesser J; Rizzo A; Mollica V; Marchetti A; Rosellini M; Sorgentoni G; Battelli N; Buti S; Porta C; Bellmunt J
    Cancer Immunol Immunother; 2024 Apr; 73(6):106. PubMed ID: 38634928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment.
    Gupta S; Andreev-Drakhlin A; Fajardo O; Fassò M; Garcia JA; Wee C; Schröder C
    J Natl Cancer Inst; 2024 Apr; 116(4):547-554. PubMed ID: 38036464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.
    Shindo T; Maehana T; Tanaka T; Hashimoto K; Kobayashi K; Takahashi A; Hotta H; Kunishima Y; Taguchi K; Tachiki H; Ito N; Matsukawa M; Kato R; Miyamoto S; Hinotsu S; Masumori N
    Int J Urol; 2022 Sep; 29(9):1010-1016. PubMed ID: 35654444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab.
    Sato R; Inamoto T; Matsushita Y; Takemura A; Uchimoto T; Sano A; Tanaka H; Ishikawa G; Watanabe K; Watanabe H; Tamura K; Motoyama D; Sugiyama T; Otsuka A; Harada KI; Azuma H; Miyake H
    Int J Urol; 2023 Sep; 30(9):730-736. PubMed ID: 36575640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
    Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice.
    Furubayashi N; Kuroiwa K; Tokuda N; Tomoda T; Morokuma F; Hori Y; Negishi T; Inoue T; Kumagai M; Nakamura M
    J Clin Med Res; 2020 May; 12(5):300-306. PubMed ID: 32489505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
    Fukuokaya W; Yanagisawa T; Hashimoto M; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Miki J; Oyama Y; Abe H; Kimura T
    Cancer Immunol Immunother; 2023 Apr; 72(4):841-849. PubMed ID: 36102985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
    Mollica V; Tassinari E; Santoni M; Marchese PV; Giunchi F; Maloberti T; Tateo V; Ricci C; Rosellini M; Marchetti A; Fiorentino M; Biase D; Massari F
    Pathol Res Pract; 2024 Jan; 253():155008. PubMed ID: 38103361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line pembrolizumab for patients with early relapsing urothelial carcinoma after perioperative chemotherapy: a retrospective analysis of bladder cancer and upper urinary tract cancer.
    Nishimura N; Miyake M; Shimizu T; Matsubara T; Miyamoto T; Sakamoto K; Yamada A; Matsumoto Y; Yoshikawa M; Ichikawa K; Omori C; Maesaka F; Oda Y; Kiba K; Tomioka A; Hosokawa Y; Tanaka M; Otani T; Fujimoto K
    Int J Clin Oncol; 2022 Nov; 27(11):1733-1741. PubMed ID: 36029377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
    Bellmunt J; Chang J; Pavilack-Kirker M; Cappelleri JC; Costa N; Esterberg E; Kearney M; Hitchens A; Candrilli SD; Ajmera M
    Clin Genitourin Cancer; 2023 Aug; 21(4):459-466. PubMed ID: 37149458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
    Etani T; Naiki T; Sugiyama Y; Nagai T; Iida K; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Okada T; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
    Oncology; 2020; 98(12):876-883. PubMed ID: 32862183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significant Improvement of Prognosis After the Advent of Immune Checkpoint Inhibitors in Patients with Advanced, Unresectable, or Metastatic Urothelial Carcinoma: A Propensity Score Matching and Inverse Probability of Treatment Weighting Analysis on Real-World Data.
    Miyake M; Nishimura N; Shimizu T; Ohnishi M; Kuwada M; Itami Y; Inoue T; Ohnishi K; Matsumoto Y; Yoshida T; Tatsumi Y; Shinohara M; Hori S; Morizawa Y; Gotoh D; Nakai Y; Anai S; Torimoto K; Aoki K; Fujii T; Tanaka N; Fujimoto K
    Cancer Manag Res; 2022; 14():623-635. PubMed ID: 35210859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.